Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unique DNA impacts on transient Expi293<sup>TM</sup>PRO expression for enhancing biotherapeutic protein production.

Frontiers in bioengineering and biotechnology·2026

Same author

Cancer Prevention Literacy Questionnaire (CPL-Q): development and validation within the World Code Against Cancer Framework.

BMC public health·2026

Same author

Correction: Creation of the European Portuguese version of the Glasgow composite measure pain Scale - short form (CMPS-SF) and initial psychometric evaluation.

BMC veterinary research·2026

Same author

Initial psychometric evaluation of the European Portuguese version of the Lincoln Canine Adaptability Resilience Scale.

PloS one·2025

Same author

The Combined Application of Intra-Articular Platelet-Rich Plasma Injections and Photobiomodulation Improves Clinical Outcomes in Dogs with Osteoarthritis-Results of a Long-Term, Double-Blinded, Crossover Study.

Veterinary sciences·2025

Same author

Creation of the European Portuguese version of the Glasgow Composite Measure Pain Scale - short form (CMPS-SF) and initial psychometric evaluation.

BMC veterinary research·2025

Same journal

Editorial: Technologies for RNA Detection.

Bio-protocol·2026

Same journal

One-Step Affinity Purification of MarathonRT Reverse Transcriptase for RNA Sequencing Applications.

Bio-protocol·2026

Same journal

Enhanced RNA-Seq Expression Profiling and Functional Enrichment in Non-model Organisms Using Custom Annotations.

Bio-protocol·2026

Same journal

Using Combined Fluorescent In Situ Hybridization With Immunohistochemistry to Co-localize mRNA in Diverse Neuronal Cell Types.

Bio-protocol·2026

Same journal

Stepwise Protocol for Alternative Splicing Analysis in Single-Cell SMART-Seq2 RNA-Seq Data.

Bio-protocol·2026

Same journal

Enriching Bacteria-Specific RNA From Host Samples Before NGS With Transcript-Capture.

Bio-protocol·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

In-Culture Antibody Capture Using Transient CHO Expression Systems.

Jing Zhou¹, Lauren Gebhardt¹, Molica Abel¹

¹BioMedicine Design, Preclinical and Translational Sciences, Pfizer Research and Development, Cambridge, MA, USA.

|June 17, 2026

Summary

This summary is machine-generated.

This study introduces a semi-automated antibody production protocol using Chinese hamster ovary (CHO) cells and magnetic bead purification. This method rapidly generates dozens of high-quality antibody candidates weekly for research screening.

Keywords:

AmMagTM Protein-A magnetic beads CHO4Tx®GenScript AmMagTM SA-Plus In-culture antibody capturing Semi-automation purification Transient gene expression

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Laboratory Scale Production and Purification of a Therapeutic Antibody

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study

Published on: August 16, 2019

Area of Science:

Biotechnology
Immunology
Protein Engineering

Background:

Therapeutic antibodies offer significant patient benefits, but discovery advances create production challenges.
High-throughput screening demands rapid production of diverse antibody candidates in specific quantities.

Purpose of the Study:

To present a semi-automated protocol for efficient, scalable antibody production.
To bridge the gap between high-throughput screening and conventional production workflows.

Main Methods:

Utilized a high-titer transient Chinese hamster ovary (CHO) cell expression system (CHO4Tx®).
Employed magnetic protein-A bead in-culture antibody capturing.
Implemented a semi-automated purification process using the GenScript AmMag™ SA Plus system.

Main Results:

Demonstrated robust and valuable routine production of dozens of antibody constructs weekly.
Achieved sufficient quality and quantity for cell-based and biophysical studies.
Protocol increases production throughput by decreasing culture volume and eliminating complex steps.

Conclusions:

The developed protocol is effective for rapid, routine production of therapeutic antibody candidates.
Magnetic bead purification is adaptable to various cell lines, including other CHO and human embryonic kidney-293 cells.
This workflow streamlines antibody production for research and development needs.